ijms-logo

Journal Browser

Journal Browser

Advances in Molecular Mechanisms of Neurodegenerative Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 30 August 2024 | Viewed by 524

Special Issue Editor


E-Mail Website
Guest Editor
Centre for Systems Health and Integrated Metabolic Research (SHiMR), School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK
Interests: neurodegeneration; proteostasis; neurodegenerative disorders; Parkinson’s disease; proteomic analysis; mitochondria; reactive oxygen species

Special Issue Information

Dear Colleagues,

Neurodegenerative diseases affect millions of people worldwide and have been recognised as a critical global health challenge. Neurodegenerative diseases comprise multiple disorders including Parkinson’s and Alzheimer’s disease and are primarily characterised by a progressive loss of neurons. There are several approved drugs for managing neurodegenerative diseases; however, a majority of these drugs only target disease symptoms. At the cellular level, oxidative stress, mitochondrial dysfunction and altered proteolysis are considered important contributors to neurodegeneration. However, more research into molecular signalling mechanism is needed to better understand the complex nature and signalling molecules/pathways involved in neuronal death. This Special Issue is dedicated to the recent research progress made in unrevealing the molecular signalling mediating cell death and survival in neurodegeneration and identifying new targets/pathways that can be exploited for the development of novel therapies to stop/slow down neuronal death.

This Special Issue is supervised by Dr. Aslihan Ugun-Klusek and assisted by our Guest Editor’s Assistant Editor Dr. Shreyasi Chatterjee (Nottingham Trent University).

Dr. Aslihan Ugun-Klusek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegeneration
  • Parkinson’s disease
  • Alzheimer’s disease
  • molecular signalling
  • neuronal death

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 537 KiB  
Review
Alzheimer’s Disease Neuropathological Change in Aged Non-Primate Mammals
by Isidro Ferrer
Int. J. Mol. Sci. 2024, 25(15), 8118; https://doi.org/10.3390/ijms25158118 - 25 Jul 2024
Viewed by 210
Abstract
Human brain aging is characterized by the production and deposition of β-amyloid (Aβ) in the form of senile plaques and cerebral amyloid angiopathy and the intracellular accumulation of hyper-phosphorylated tau (Hp-tau) to form neurofibrillary tangles (NFTs) and dystrophic neurites of senile plaques. The [...] Read more.
Human brain aging is characterized by the production and deposition of β-amyloid (Aβ) in the form of senile plaques and cerebral amyloid angiopathy and the intracellular accumulation of hyper-phosphorylated tau (Hp-tau) to form neurofibrillary tangles (NFTs) and dystrophic neurites of senile plaques. The process progresses for years and eventually manifests as cognitive impairment and dementia in a subgroup of aged individuals. Aβ is produced and deposited first in the neocortex in most aged mammals, including humans; it is usually not accompanied by altered behavior and cognitive impairment. Hp-tau is less frequent than Aβ pathology, and NFTs are rare in most mammals. In contrast, NFTs are familiar from middle age onward in humans; NFTs first appear in the paleocortex and selected brain stem nuclei. NFTs precede for decades or years Aβ deposition and correlate with dementia in about 5% of individuals at the age of 65 and 25% at the age of 85. Based on these comparative data, (a) Aβ deposition is the most common Alzheimer’s disease neuropathological change (ADNC) in the brain of aged mammals; (b) Hp-tau is less common, and NFTs are rare in most aged mammals; however, NFTs are the principal cytoskeletal pathology in aged humans; (c) NFT in aged humans starts in selected nuclei of the brain stem and paleocortical brain regions progressing to the most parts of the neocortex and other regions of the telencephalon; (d) human brain aging is unique among mammalian species due to the early appearance and dramatic progression of NFTs from middle age onward, matching with cognitive impairment and dementia in advanced cases; (e) neither mammalian nor human brain aging supports the concept of the amyloid cascade hypothesis. Full article
(This article belongs to the Special Issue Advances in Molecular Mechanisms of Neurodegenerative Diseases)
Show Figures

Figure 1

Back to TopTop